Given that SRSF1 acts as an oncoprotein and its inhibition by decoy oligonucleotides activated the p38-MAPK stress pathway, we predicted that treatment of cancer cells with SRSF1 decoy oligonucleotides would reverse the transformed phenotype of these cells. This evidence concerns the gene SRSF1 and cancer.